Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of NTI164 in Healthy Adult Volunteers
NCT06713447Phase 1Completed
- Sponsor
- Fenix Innovation Group
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NTI164 in neurological disorders, sponsored by Fenix Innovation Group. Primary endpoint: Peak plasma concentration up to 21 days. Started Feb 2024; status: completed.
02
Drugs
NTI164
03
Conditions
neurological disorders
Beyond the preview
Go deeper on NCT06713447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713447.